JP2022529929A5 - - Google Patents

Info

Publication number
JP2022529929A5
JP2022529929A5 JP2021561599A JP2021561599A JP2022529929A5 JP 2022529929 A5 JP2022529929 A5 JP 2022529929A5 JP 2021561599 A JP2021561599 A JP 2021561599A JP 2021561599 A JP2021561599 A JP 2021561599A JP 2022529929 A5 JP2022529929 A5 JP 2022529929A5
Authority
JP
Japan
Prior art keywords
antibody
humanized anti
seq
patient
domain described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529929A (ja
JP7778567B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/028861 external-priority patent/WO2020215019A1/en
Publication of JP2022529929A publication Critical patent/JP2022529929A/ja
Publication of JP2022529929A5 publication Critical patent/JP2022529929A5/ja
Priority to JP2025122188A priority Critical patent/JP2025169256A/ja
Application granted granted Critical
Publication of JP7778567B2 publication Critical patent/JP7778567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021561599A 2019-04-17 2020-04-17 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 Active JP7778567B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025122188A JP2025169256A (ja) 2019-04-17 2025-07-22 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835349P 2019-04-17 2019-04-17
US62/835,349 2019-04-17
PCT/US2020/028861 WO2020215019A1 (en) 2019-04-17 2020-04-17 Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025122188A Division JP2025169256A (ja) 2019-04-17 2025-07-22 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法

Publications (3)

Publication Number Publication Date
JP2022529929A JP2022529929A (ja) 2022-06-27
JP2022529929A5 true JP2022529929A5 (https=) 2023-04-25
JP7778567B2 JP7778567B2 (ja) 2025-12-02

Family

ID=72837950

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561599A Active JP7778567B2 (ja) 2019-04-17 2020-04-17 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
JP2025122188A Pending JP2025169256A (ja) 2019-04-17 2025-07-22 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025122188A Pending JP2025169256A (ja) 2019-04-17 2025-07-22 α４β７阻害薬及びＩＬ－２３阻害薬の併用療法

Country Status (5)

Country Link
US (1) US20230096620A1 (https=)
EP (1) EP3956358A4 (https=)
JP (2) JP7778567B2 (https=)
MA (1) MA55735A (https=)
WO (1) WO2020215019A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159633A1 (en) * 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2026058045A1 (en) * 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CA3255406A1 (en) * 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
WO2017106595A1 (en) * 2015-12-18 2017-06-22 Sciadonics, Inc. Lipid formulations containing bioactive fatty acids and a non-fatty acid anti-inflammatory agent
US10918716B2 (en) * 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
US20200253506A1 (en) * 2016-12-14 2020-08-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
AU2018256840A1 (en) * 2017-04-28 2019-11-07 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)
US20230033021A1 (en) * 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Similar Documents

Publication Publication Date Title
JP7579227B2 (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP7331219B2 (ja) 潰瘍性大腸炎を治療する方法
JP2022529929A5 (https=)
CN115768516A (zh) 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
CN114173819A (zh) 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
JP2022188083A (ja) 化膿性汗腺炎の処置
CN112689512B (zh) 用于治疗银屑病的组合物和方法
JP2022523530A (ja) 化膿性汗腺炎の治療のための抗ＩＬ－α抗体
WO2022075476A1 (en) Method for treating ox40 related disease
JP2023522196A (ja) 化膿性汗腺炎の治療
JP2022529266A (ja) 乾癬性関節炎に罹患している対象者の治療方法
JP7093940B2 (ja) 全身性強皮症治療用医薬組成物
JP7297930B2 (ja) クローン病を治療する方法に使用するためのミリキズマブ
CN120204387A (zh) 治疗银屑病的方法
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
JP2020517648A5 (https=)
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
WO2024077113A1 (en) Methods of treating fatigue in ulcerative colitis
JP2025537966A (ja) 潰瘍性大腸炎を治療する方法
WO2026060205A1 (en) PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
US20210069313A1 (en) Vaccination against diabetes, obesity and complications thereof
HK40052952A (en) Compositions and methods for treatment of psoriasis
Swendrowski Ustekinumab: a review of the effectiveness of targeting interleukin-12/23P40 in psoriasis and other immune-mediated diseases
WO2017102927A1 (en) Vaccination against diabetes, obesity and complications thereof